BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31247675)

  • 1. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Sakamoto K; Shiba N; Deguchi T; Kiyokawa N; Hashii Y; Moriya-Saito A; Tomizawa D; Taga T; Adachi S; Horibe K; Imamura T
    Br J Haematol; 2019 Nov; 187(3):372-376. PubMed ID: 31247675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of CD19 and CD56 in AML Patients with RUNX1-RUNX1T1 Mutation and Its Clinical Significance].
    Hu ZL; Zhang F; Huang BJ; Pan SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):727-732. PubMed ID: 29950211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N
    Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
    Ommen HB; Ostergaard M; Yan M; Braendstrup K; Zhang DE; Hokland P
    Eur J Haematol; 2010 Feb; 84(2):128-32. PubMed ID: 19891700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
    Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
    Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
    Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 13. A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia.
    Zampini M; Bisio V; Leszl A; Putti MC; Menna G; Rizzari C; Pession A; Locatelli F; Basso G; Tregnago C; Pigazzi M
    Br J Haematol; 2018 Oct; 183(2):298-301. PubMed ID: 28961307
    [No Abstract]   [Full Text] [Related]  

  • 14. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
    Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
    Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Related Factors Affecting Long-term Prognosis of AML Children with Positive RUNX1-RUNX1T1].
    Teng GY; Qu WJ; Zhang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1767-1773. PubMed ID: 31839036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning derived genomics driven prognostication for acute myeloid leukemia with
    Shaikh AF; Kakirde C; Dhamne C; Bhanshe P; Joshi S; Chaudhary S; Chatterjee G; Tembhare P; Prasad M; Roy Moulik N; Gokarn A; Bonda A; Nayak L; Punatkar S; Jain H; Bagal B; Shetty D; Sengar M; Narula G; Khattry N; Banavali S; Gujral S; P G S; Patkar N
    Leuk Lymphoma; 2020 Dec; 61(13):3154-3160. PubMed ID: 32757686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
    Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RUNX1-RUNX1T1-positive acute myeloid leukaemia presenting as bilateral proptosis and multiple cranial nerve palsy.
    Totadri S; Bhatia P; Sreedharanunni S
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center.
    Gupta R; Yadav S; Parashar Y; Rahman K; Singh MK; Chandra D; Gupta A; Nityanand S
    Int J Lab Hematol; 2020 Feb; 42(1):37-45. PubMed ID: 31725954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.